PURPOSE:Amitriptyline is frequently used to treat patients with interstitial cystitis/painful bladder syndrome. The evidence to support this practice is derived mainly from a small, single site clinical trial and case reports. MATERIALS AND METHODS: We conducted a multicenter, randomized, double-blind, placebo controlled clinical trial of amitriptyline in subjects with interstitial cystitis/painful bladder syndrome who were naïve to therapy. Study participants in both treatment arms received a standardized education and behavioral modification program. The drug dose was increased during a 6-week period from 10 up to 75 mg once daily. The primary outcome was a patient reported global response assessment of symptom improvement evaluated after 12 weeks of treatment. RESULTS:A total of 271 subjects were randomized and 231 (85%) provided a global response assessment at 12 weeks of followup. Study participants were primarily women (83%) and white (74%), with a median age of 38 years. In an intent to treat analysis (271) the rate of response of subjects reporting moderate or marked improvement from baseline in the amitriptyline and placebo groups was 55% and 45%, respectively (p = 0.12). Of the subgroup of subjects (207) who achieved a drug dose of at least 50 mg, a significantly higher response rate was observed in the amitriptyline group (66%) compared to placebo (47%) (p = 0.01). CONCLUSIONS: When all randomized subjects were considered, amitriptyline plus an education and behavioral modification program did not significantly improve symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. However, amitriptyline may be beneficial in persons who can achieve a daily dose of 50 mg or greater, although this subgroup comparison was not specified in advance. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
RCT Entities:
PURPOSE:Amitriptyline is frequently used to treat patients with interstitial cystitis/painful bladder syndrome. The evidence to support this practice is derived mainly from a small, single site clinical trial and case reports. MATERIALS AND METHODS: We conducted a multicenter, randomized, double-blind, placebo controlled clinical trial of amitriptyline in subjects with interstitial cystitis/painful bladder syndrome who were naïve to therapy. Study participants in both treatment arms received a standardized education and behavioral modification program. The drug dose was increased during a 6-week period from 10 up to 75 mg once daily. The primary outcome was a patient reported global response assessment of symptom improvement evaluated after 12 weeks of treatment. RESULTS: A total of 271 subjects were randomized and 231 (85%) provided a global response assessment at 12 weeks of followup. Study participants were primarily women (83%) and white (74%), with a median age of 38 years. In an intent to treat analysis (271) the rate of response of subjects reporting moderate or marked improvement from baseline in the amitriptyline and placebo groups was 55% and 45%, respectively (p = 0.12). Of the subgroup of subjects (207) who achieved a drug dose of at least 50 mg, a significantly higher response rate was observed in the amitriptyline group (66%) compared to placebo (47%) (p = 0.01). CONCLUSIONS: When all randomized subjects were considered, amitriptyline plus an education and behavioral modification program did not significantly improve symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. However, amitriptyline may be beneficial in persons who can achieve a daily dose of 50 mg or greater, although this subgroup comparison was not specified in advance. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: E Rovner; K J Propert; C Brensinger; A J Wein; M Foy; A Kirkemo; J R Landis; J W Kusek; L M Nyberg Journal: Urology Date: 2000-12-20 Impact factor: 2.649
Authors: Kathryn H Schmitz; Tamara Bavendam; Sonya S Brady; Linda Brubaker; Kathryn Burgio; Bernard L Harlow; Aimee James; Emily S Lukacz; Janis M Miller; Diane K Newman; Mary H Palmer; Kyle Rudser; Siobhan Sutcliffe Journal: Neurourol Urodyn Date: 2020-04-22 Impact factor: 2.696
Authors: Kevin M Hellman; Avisek Datta; Nicole D Steiner; Julia N Kane Morlock; Ellen F Garrison; Daniel J Clauw; Frank F Tu Journal: Am J Obstet Gynecol Date: 2018-04-25 Impact factor: 8.661
Authors: J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis Journal: Nat Rev Urol Date: 2019-03 Impact factor: 14.432
Authors: Yan Zhang; Shun Li; Todd Yecies; Tara Morgan; Haotian Cai; Natalie Pace; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: Am J Physiol Renal Physiol Date: 2019-01-23
Authors: Mari Imamura; Neil W Scott; Sheila A Wallace; Joseph A Ogah; Abigail A Ford; Yann A Dubos; Miriam Brazzelli Journal: Cochrane Database Syst Rev Date: 2020-07-30